High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients With Acute Type 1 Respiratory Failure
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 108
- 试验地点
- 1
- 主要终点
- Correction of hypoxia in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure
研究概览
简要总结
compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure
详细描述
A prospective randomized controlled trial was conducted on 108 patients with COVID 19 pneumonia with acute hypoxemic respiratory failure at Mansoura University Hospitals to compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure, focusing on the need for invasive mechanical ventilation (IMV) and 28-day mortality. Patients were randomized into two equal groups: HVNI group and CPAP group. Baseline characteristics, respiratory parameters, and clinical outcomes were recorded.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged above 18 years with COVID 19 pneumonia with acute type 1 respiratory failure were included.
排除标准
- •patients with hypercapnic respiratory failure.
- •patients with a disturbed level of consciousness and/or a high risk of aspiration
- •individuals with hypotension
- •patients requiring invasive mechanical ventilation.
研究组 & 干预措施
Continuous Positive Airway Pressure
COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received Continuous Positive Airway Pressure
干预措施: Continuous Positive Airway Pressure (Device)
High Velocity Nasal Insufflation
COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received High Velocity Nasal Insufflation
干预措施: High Velocity Nasal Insufflation (Device)
结局指标
主要结局
Correction of hypoxia in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure
时间窗: 6 months
assessment of efficacy of High Velocity Nasal Insufflation versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure
次要结局
未报告次要终点